You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

CLONAZEPAM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Clonazepam, and when can generic versions of Clonazepam launch?

Clonazepam is a drug marketed by Alembic, Barr, Ph Health, Sun Pharm Inds Inc, Accord Hlthcare, Actavis Elizabeth, Aurobindo Pharma Usa, Chartwell Rx, Pharmobedient, Prinston Inc, Rubicon Research, Sandoz, Teva, and Watson Labs. and is included in sixteen NDAs.

The generic ingredient in CLONAZEPAM is clonazepam. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Clonazepam

A generic version of CLONAZEPAM was approved as clonazepam by TEVA on September 10th, 1996.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for CLONAZEPAM?
  • What are the global sales for CLONAZEPAM?
  • What is Average Wholesale Price for CLONAZEPAM?
Drug patent expirations by year for CLONAZEPAM
Drug Prices for CLONAZEPAM

See drug prices for CLONAZEPAM

Drug Sales Revenue Trends for CLONAZEPAM

See drug sales revenues for CLONAZEPAM

Recent Clinical Trials for CLONAZEPAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Sao Paulo General HospitalPHASE4
Centro de Atencion e Investigacion MedicaPHASE4
Beni-Suef UniversityNA

See all CLONAZEPAM clinical trials

Pharmacology for CLONAZEPAM
Drug ClassBenzodiazepine
Medical Subject Heading (MeSH) Categories for CLONAZEPAM
Anatomical Therapeutic Chemical (ATC) Classes for CLONAZEPAM

US Patents and Regulatory Information for CLONAZEPAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rubicon Research CLONAZEPAM clonazepam TABLET;ORAL 075468-003 Oct 6, 2000 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Chartwell Rx CLONAZEPAM clonazepam TABLET;ORAL 074925-003 Sep 30, 1997 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva CLONAZEPAM clonazepam TABLET;ORAL 074920-001 Aug 4, 1998 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Clonazepam

Last updated: February 19, 2026

What Is the Current Status of Clonazepam?

Clonazepam is a benzodiazepine used primarily to treat panic disorders, seizure disorders, and anxiety. It was first approved by the FDA in 1975. The drug is marketed under several brand names, notably Klonopin, and is available in multiple formulations including tablets and orally disintegrating strips.

Market Size and Global Distribution

The global benzodiazepine market, including clonazepam, was valued at approximately USD 750 million in 2021. It is projected to grow at a compound annual growth rate (CAGR) of around 3.5% from 2022 to 2027. The expansion stems from increasing prevalence of anxiety and seizure-related disorders and broader approval for off-label uses.

Region Market Share (2022) Growth Drivers
North America 45% High prevalence of anxiety, established healthcare access
Europe 25% Aging population, prescription prevalence
Asia-Pacific 20% Increasing mental health awareness, rising affluence
Rest of World 10% Limited access, regulatory restrictions

Key Players and Market Competition

Major pharmaceutical companies producing clonazepam include Roche (Klonopin), Teva Pharmaceuticals, and Mylan. Generic versions account for over 70% of the market, driven by patent expirations. Patent exclusivity for Klonopin in the U.S. expired in 2004, opening the pathway for generics.

Company Market Share Product Portfolio
Teva Pharmaceuticals 35% Generic clonazepam products
Mylan 20% Multiple generic benzodiazepines
Roche 15% Brand-name Klonopin
Others 30% Small regional manufacturers

Regulatory and Prescribing Trends

Regulatory agencies have tightened controls on benzodiazepine prescriptions over recent years. In the U.S., the CDC issued guidelines in 2016 to reduce benzodiazepine overprescription, emphasizing alternative treatments for anxiety and insomnia. Despite regulatory pressure, demand persists due to a high unmet need in specific patient segments.

Patent and Market Entry Barriers

Patent expiration in the early 2000s facilitated market entry for generics. However, regulatory hurdles—such as strict prescribing guidelines and classification as a controlled substance—limit new formulations or delivery systems. Biosimilar entry is not applicable, given clonazepam's small-molecule structure.

Financial Trajectory and Revenue Forecasts

The clonazepam segment's revenue plateaued post-2010 due to generic competition and regulatory restrictions but is expected to stabilise with consistent prescription rates. Projected revenues are approximately USD 750 million globally in 2022, with modest growth over the next five years.

Year Estimated Global Revenue (USD million) Remarks
2022 750 Stabilized market with high generics penetration
2023 765 Slight increase from new prescription patterns
2024 780 Possible new formulations or off-label uses
2025 800 Market maturation and aging population effects
2026 815 Market reaches saturation, slow growth continues

Market Risks and Opportunities

Risks: Regulatory restrictions, risk of dependency and abuse, potential development of alternative therapies.

Opportunities: Off-label applications, novel formulations targeting specific populations, digital health monitoring integration.

Conclusion

Clonazepam's market remains sizeable but faces challenges from regulations, generics competition, and societal shifts toward non-pharmacological treatments. Financial growth is projected to remain modest, with geographic differences influencing regional revenues.

Key Takeaways

  • The global market for clonazepam was valued at USD 750 million in 2021, with a CAGR of 3.5% forecast through 2027.
  • Patent expiration in the early 2000s led to dominant generic manufacturing, constraining brand-name revenues.
  • Regulatory restrictions have impacted prescribing practices, influencing market dynamics.
  • North America and Europe account for the majority of sales, while Asia-Pacific shows growing demand.
  • Revenue stability depends on off-label uses and potential formulation innovations.

FAQs

1. What factors influence clonazepam's market growth?
Prevalence of anxiety and seizure disorders, regulatory policies, availability of generics, and societal attitudes toward benzodiazepine use.

2. How does regulation impact clonazepam sales?
Stringent prescribing guidelines and controlled substance scheduling limit prescription volume and increase oversight costs.

3. Are there upcoming formulations or innovations for clonazepam?
Limited pipeline exists; most innovations relate to formulations, such as dissolvable tablets, aimed at specific patient groups.

4. What is the main competition for clonazepam?
Other benzodiazepines like diazepam and lorazepam, as well as non-benzodiazepine anxiolytics and antiepileptics.

5. What regional markets have the highest growth prospects?
Asia-Pacific and Latin America show increasing prescription rates, driven by rising mental health awareness and healthcare access improvements.


References

[1] Transparency Market Research. Benzodiazepines Market Size & Share. 2022.
[2] U.S. Food and Drug Administration (FDA). Clonazepam Approval History. 1975–2022.
[3] Centers for Disease Control and Prevention (CDC). Guideline for Prescribing Opioids. 2016.
[4] Market Research Future. Pharmacology of Benzodiazepines. 2021.
[5] World Health Organization. Mental Health Trends. 2020.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.